Skip navigation
Please use this identifier to cite or link to this item: https://repositorio.unb.br/handle/10482/40848
Files in This Item:
File Description SizeFormat 
CAPITULO_HydroxychloroquineFightingCOVID.pdf1,17 MBAdobe PDFView/Open
Title: Hydroxychloroquine in fighting COVID-19 : What led WHO to suspend clinical trial of drug?
Authors: Pacheco, Thyago José Arruda
Souza, Danielle Galdino de
Faria, Raquel Santos
Andrade, Laise Rodrigues de
Assunto:: Hidroxicloroquina
Testes
Covid-19
SARS-CoV-2
Issue Date: 2020
Publisher: Editora Poisson
Citation: PACHECO, Thyago José Arruda; SOUZA, Danielle Galdino de; FARIA, Raquel Santos; ANDRADE, Laise Rodrigues de. Hydroxychloroquine in fighting COVID-19: what led WHO to suspend clinical trial of drug?. In: ALVES, Gleica Soyan Barbosa; OLIVEIRA, Eliene de (org.). Tópicos em ciências da saúde. Belo Horizonte: Editora Poisson, 2020. v. 21, cap. 21, p. 158-165. DOI: 10.36229/978-65-5866-037-8. Disponível em: https://www.poisson.com.br/livros/saude/volume21/Saude_vol21.pdf. Acesso em: 30 abr. 2021.
Abstract: Purpose: On March 11, 2020 the pandemic status of COVID-19 (Coronavirus Disease 2019) was declared. The milestone of thousands of daily deaths from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reached worldwide. So far, there is still no proven effective treatment against this disease. This study summarizes the main clinical findings on the use of hydroxychloroquine (HCQ) to treat COVID-19. The goal is to gather the evidence that led WHO to suspend the HCQ arm of its Solidarity Trial, contributing to the understanding of its denouement. Methods: LitCovid platform was searched for the term "hydroxychloroquine” in the “treatment” field. All clinical studies published in the period from January 1st to June 17th were included in the review. Results: We included ten articles on HCQ in COVID-19 positive patients (eight non-randomized and two randomized clinical studies). Most studies did not report a benefit in the use of HCQ. There is no evidence of decreased risk of intubation or death, and in some cases adverse effects have been reported, such as abnormal liver function, transient blurred vision, diarrhea. Conclusions: The overview of the available data on HCQ in COVID-19 patients can guide future studies, still needed to support public policies and health authorities in fighting COVID-19.
Licença:: Autorização concedida pelo representante legal da Editora Poisson a Universidade de Brasília (UNB), em 23 de abril de 2021, para disponibilizar o capítulo “Hydroxychloroquine in fighting COVID-19: What led WHO to suspend clinical trial of drug?” do livro Tópicos em Ciências da Saúde - Volume 21 no Repositório Institucional da Universidade de Brasília, para uso sem fins comerciais e livre acesso. A cessão é para o Repositório Institucional da Universidade de Brasília é sem ressarcimento de direitos autorais, conforme disposições legais previstas na Lei no 9.610, de 19 de fevereiro de 1998.
DOI: 10.36229/978-65-5866-037-8
Appears in Collections:GEM - Livros e capítulos de livros
UnB - Covid-19

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/40848/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.